Pantoprazole is a nucleon pump matter that decreases the quantity of acid made within the abdomen.
Pantoprazole is employed to treat erosive inflammation (damage to the muscle system from abdomen acid), and different conditions involving excess abdomen acid like Zollinger-Ellison syndrome.

Pantoprazole isn’t for immediate relief of symptom symptoms.

Submit your review
1
2
3
4
5
Submit
     
Cancel

Create your own review

Average rating:  
 0 reviews
  • Protonix, Protonix IV
  • As well as its needed effects, pantoprazole may cause unwanted side effects that require medical attention.

    If any of the following side effects occur while taking pantoprazole, check with your doctor immediately:

    Less common
    Abdominal or stomach pain
    blurred vision
    dry mouth
    flushed, dry skin
    fruit-like breath odor
    increased hunger
    increased thirst
    increased urination
    nausea
    sweating
    troubled breathing
    unexplained weight loss
    vomiting
    Incidence not known
    Absence of or decrease in body movements
    blindness
    blistering, peeling, or loosening of the skin
    bloating
    bloody or cloudy urine
    bloody, black, or tarry stools
    blurred vision
    chills
    clay-colored stools
    constipation
    continuous ringing or buzzing or other unexplained noise in the ears
    cough
    dark-colored urine
    decreased vision
    diarrhea
    difficulty with speaking
    difficulty with swallowing
    dizziness or lightheadedness
    drowsiness
    fast heartbeat
    feeling of constant movement of self or surroundings
    fever
    general feeling of tiredness or weakness
    greatly decreased frequency of urination or amount of urine
    headache
    hearing loss
    high fever
    hives, itching, or skin rash
    indigestion
    joint pain
    large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
    light-colored stools
    loss of appetite
    mood or mental changes
    muscle cramps
    muscle pain or stiffness
    muscle spasms (tetany) or twitching
    pains in the stomach, side, or abdomen, possibly radiating to the back
    pale skin
    puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
    red skin lesions, often with a purple center
    red, irritated eyes
    seizures
    sensation of spinning
    sore throat
    sores, ulcers, or white spots on the lips or in the mouth
    stomach pain, continuing
    swelling of the feet or lower legs
    swollen glands
    tightness in the chest
    trembling
    unexplained bleeding or bruising
    unpleasant breath odor
    unusual tiredness or weakness
    vomiting of blood
    yellow eyes or skin
  • Usual Adult Dose for Erosive Esophagitis Treatment of Erosive Esophagitis: 40 mg orally once a day for up to 8 weeks; however an additional 8 weeks may be considered for patients who have not healed after the initial treatment. Safety and efficacy beyond 16 weeks of therapy have not been established. Maintenance of Healing of Erosive Esophagitis: 40 mg orally once a day. Controlled studies have been limited to 12 months of pantoprazole therapy. Usual Adult Dose for Gastroesophageal Reflux Disease Parenteral: 40 mg once a day for 7 to 10 days, administered via intravenous infusion over a period of 15 minutes. Intravenous therapy should be discontinued as soon as the patient is able to resume oral therapy. Oral: 40 mg orally once a day, for short-term administration (up to 8 weeks); however an additional 8 weeks may be considered for patients who have not healed after the initial treatment. Safety and efficacy beyond 16 weeks of therapy have not been established. Usual Adult Dose for Duodenal Ulcer Study (n=54) 40 mg orally once a day, dose was increased every 12 weeks by 40 mg increments to a maximum of 120 mg per day, for 28 weeks. Data have revealed that monotherapy with daily doses of 40 mg have been associated with complete duodenal ulcer healing in up to 87% and 94% of patients after 4 weeks and 8 weeks respectively. Usual Adult Dose for Gastric Ulcer 40 mg orally once a day. Data have revealed that monotherapy with daily doses of 40 mg have been associated with complete gastric ulcer healing in up to 87% and 97% of patients after 4 weeks and 8 weeks respectively. Usual Adult Dose for Helicobacter pylori Infection Study (n=242) - Triple therapy: 40 mg orally twice daily for 7 days, commonly in conjunction with clarithromycin and either amoxicillin or metronidazole to eradicate Helicobacter pylori, followed with 40 mg pantoprazole orally once daily until day 28. Triple therapy has resulted in eradication rates of greater than 95%. The QUADRATE Study (n=405) - Quadruple therapy: 40 mg orally twice daily for 7 days, concomitantly with bismuth subcitrate and tetracycline, both four times daily, and metronidazole 200 mg three times daily and 400 mg at bedtime. Helicobacter Pylori eradication was achieved in 82% of patients. Usual Adult Dose for Zollinger-Ellison Syndrome Parenteral: 80 mg every 12 hours, administered by 15-minute infusion. Daily doses higher than 240 mg administered in equally divided doses by 15-minute infusion, or administered for more than 6 days have not been studied. Oral: 40 mg twice daily, to a maximum of 240 mg per day. Some patients have received treatment with pantoprazole for more than 2 years. Usual Adult Dose for Stress Ulcer Prophylaxis Study (n=21) - Stress Ulcer bleeding prophylaxis in the Critical Care Setting: 80 mg twice daily, as a bolus infusion over a period of 15 minutes, to a maximum daily dose of 240 mg, divided into three equal doses. Study (n=20 ) - Peptic Ulcer rebleeding prophylaxis after hemostasis in the Critical Care Setting: 80 mg IV bolus, followed by continuous infusion of 8 mg/hr for 3 days, after which therapy may be continued with an oral PPI. Usual Adult Dose for Peptic Ulcer Study (n=21) - Stress Ulcer bleeding prophylaxis in the Critical Care Setting: 80 mg twice daily, as a bolus infusion over a period of 15 minutes, to a maximum daily dose of 240 mg, divided into three equal doses. Study (n=20 ) - Peptic Ulcer rebleeding prophylaxis after hemostasis in the Critical Care Setting: 80 mg IV bolus, followed by continuous infusion of 8 mg/hr for 3 days, after which therapy may be continued with an oral PPI.